Curcumin and capsaicin regulate apoptosis and alleviate intestinal inflammation induced by *Clostridioides difficile* in vitro

Masoumeh Azimirad¹, Maryam Noori¹, Fahimeh Azimirad¹, Fatemeh Gholami¹, Kaveh Naseri¹, Abbas Yadegar¹*, Hamid Asadzadeh Aghdaei² and Mohammad Reza Zali³

**Abstract**

**Background:** The dramatic upsurge of *Clostridioides difficile* infection (CDI) by hypervirulent isolates along with the paucity of effective conventional treatment call for the development of new alternative medicines against CDI. The inhibitory effects of curcumin (CCM) and capsaicin (CAP) were investigated on the activity of toxigenic cell-free supernatants (Tox-S) of *C. difficile* RT 001, RT 126 and RT 084, and culture-filtrate of *C. difficile* ATCC 700057.

**Methods:** Cell viability of HT-29 cells exposed to varying concentrations of CCM, CAP, *C. difficile* Tox-S and culture-filtrate was assessed by MTT assay. Anti-inflammatory and anti-apoptotic effects of CCM and CAP were examined by treatment of HT-29 cells with *C. difficile* Tox-S and culture-filtrate. Expression of BCL-2, SMAD3, NF-κB, TGF-β and TNF-α genes in stimulated HT-29 cells was measured using RT-qPCR.

**Results:** *C. difficile* Tox-S significantly (*P* < 0.05) reduced the cell viability of HT-29 cells in comparison with untreated cells. Both CAP and CCM significantly (*P* < 0.05) downregulated the gene expression level of BCL-2, SMAD3, NF-κB, TGF-β and TNF-α in Tox-S treated HT-29 cells. Moreover, the gene expression of TGF-β decreased in Tox-S stimulated HT-29 cells by both CAP and CCM, although these reductions were not significantly different (*P* > 0.05).

**Conclusion:** The results of the present study highlighted that CCM and CAP can modulate the inflammatory response and apoptotic effects induced by Tox-S from different clinical *C. difficile* strains in vitro. Further studies are required to accurately explore the anti-toxin activity of natural components, and their probable adverse risks in clinical practice.

**Keywords:** *Clostridioides difficile* infection, Curcumin, Capsaicin, Inflammation, Apoptosis, Tox-S

---

**Background**

*Clostridioides* (*Clostridium*) *difficile* is considered to be the leading cause of nosocomial diarrhea with high morbidity and mortality worldwide [1]. *C. difficile* infection (CDI) caused by toxigenic strains leads to complications of the disease ranging from asymptomatic colonization to potentially life-threatening pseudomembranous colitis and toxic megacolon [2–4]. Typically, predisposition to CDI occurs following the disruption of normal gut microbiota during or after broad-spectrum antimicrobials treatment, germination of *C. difficile* spores into vegetative cells and finally toxin production in the intestine [5].

Toxigenic strains of *C. difficile* cause intestinal inflammation with the secretion of two major enterotoxins with cytotoxic properties, toxin A (TcdA) and toxin B (TcdB),...
that belong to the large clostridial glycosylating toxin (LCGT) family [6, 7]. Both toxins, particularly TcdA, can glucosylate the Rho family GTPases, and thereby result in rearrangement of the actin cytoskeleton leading to cell rounding and apoptosis in intestinal epithelial cells (IECs) [8, 9]. Furthermore, secretion of these toxins into the gastrointestinal tract provokes a complex cascade of cellular events, which results in induction of inflammatory response and loss of epithelial integrity [10–13].

Currently, vancomycin, metronidazole and fidaxomicin are the most recommended anti-CDI antibiotics globally [14, 15]. Despite notable efficacy of vancomycin and metronidazole against *C. difficile*, which are regarded as the first-line therapies especially in developing countries, they are widely associated with high recurrence rate (20–40%) of CDI (rCDI) [16, 17]. In recent years, a new bactericidal narrow-spectrum antibiotic, fidaxomicin, has been introduced as a highly effective option to prevail over the rCDI cases [18, 19]. However, its markedly higher cost compared to conventional anti-CDI antibiotics has limited the widespread use of this antimicrobial agent [20]. Moreover, rapid emergence of hypervirulent *C. difficile* strains and their rising antimicrobial resistance have led to suboptimal clinical outcomes and even resulted in CDI treatment failures globally [21]. Thereby, a plethora of efforts are devoted to explore new promising therapies and more effective preventative interventions to overcome CDI [14]. A growing number of recent studies have focused on pharmacological actions of plant-derived compounds, particularly those included in human diet [22–26]. Moreover, herbal-derived compounds are regarded as safe and less toxic therapeutic candidates, which can target cellular viability of microorganisms and are capable to modulate toxin production in pathogenic microbes [27, 28]. Two well-known plant-derived compounds, curcumin (CCM), and capsaicin (CAP) have frequently been studied for their pharmacological actions [29, 30]. CCM, a natural phytoconstituent extracted from the rhizomes of turmeric (*Curcuma longa*), is found to possess a wide array of biological features including anti-oxidant, anti-tumor and also anti-inflammatory properties [31–33]. Furthermore, CCM and its derivatives, bisdemethoxycurcumin and demethoxycurcumin have been shown to exert various pharmacological functions, such as anti-oxidant, anti-tumor and also anti-obesity properties similar to CCM [30, 38]. Moreover, CAP has attracted much interest due to its potential antimicrobial properties against various bacterial pathogens [39]. In view of the imperative requirement of new anti-clostridial treatments, we examined the antimicrobial activities of CCM and CAP on three toxigenic *C. difficile* clinical strains (RT 001, RT 126, RT 084) and *C. difficile* ATCC 700057 (RT 038) as non-toxigenic control. Furthermore, we assessed the inhibitory effects of these natural products on toxin-mediated cytotoxicity and apoptosis in Vero and HT-29 cells treated with culture-filtrate and cell-free supernatant (Tox-S) of aforementioned strains.

**Material and methods**

**Bacterial strains and growth conditions**

The four *C. difficile* strains that were used in this study included non-toxigenic *C. difficile* ATCC 700057 (*A−B+CDT−*) and toxigenic clinical isolates of *C. difficile* RT 001 (*A+B−CDT+*), RT 126 (*A−B+CDT+*), RT 084 (*A−B−CDT−*). *C. difficile* strains were obtained from Department of Anaerobic Bacteriology in Research Institute for Gastroenterology and Liver Diseases in Tehran, Iran. All samples were cultured on cycloserine-cefoxitin-fructose agar (CCFA, Mast) supplemented with 7% horse blood under anaerobic conditions of 85% N2, 10% CO2 and 5% H2 (Anoxomat® Gas Exchange System, Mart Microbiology BV) at 37 °C for 48–72 h after an alcohol shock treatment [40].

**Antibacterial agents**

Two natural products, CAP and CCM were dominated for investigation based on previously reported evidence in literature, their current popularity, and feasibility. CAP and CCM powders were purchased from Sigma Chemical Co. (USA), and stock solutions of products were prepared in 20% dimethyl sulfoxide (DMSO) as previously described [41]. Prior to use, different concentrations of CAP (10, 20, 50, 75, 128 and 256 μM) and CCM (5, 10, 20, 30, 60, 128 and 256 μM) were freshly prepared in sterile distilled water (SDW). Vancomycin (VAN), metronidazole (MET) and fidaxomicin (FDX) were used as antimicrobial controls in susceptibility testing.

**Preparation of Tox-S and culture-filtrate**

The culture-filtrate and Tox-S of *C. difficile* strains were obtained as described previously with slight modification [42]. *C. difficile* strains were cultured on CCFA medium for 48 h, from which suspensions equivalent in turbidity to a 2 McFarland standard were prepared in 0.85% sterile saline. A volume of 100 μl of each suspension was inoculated into a 10 ml pre-reduced brain heart infusion (BHI)
broth, and incubated for 5 h under anaerobic conditions. Then, the broth cultures were aseptically sealed and incubated for a further 5 days at 37 °C in a shaking incubator (Labtech, Korea) with shaking at 120 revolutions per minute (rpm). After incubation, cultures were centrifuged at 4000 × g for 5 min and the supernatants were passed through a 0.22 μm-pore size Millipore filter to remove cells and debris. The presence of C. difficile toxins A and B in the supernatant of toxigenic strains was evaluated by enzyme-linked immunosorbent assay (ELISA, Generic Assays, Germany) according to the manufacturers' instructions.

**Determination of minimum inhibitory concentration (MIC)**
The MIC for natural products and comparator antimicrobial agents were measured using the broth microdilution method and agar dilution method, respectively as previously described [41, 43]. Briefly, two-fold serial dilutions (0.5 to 256 μM) of each product were prepared across a 96-well plate in pre-reduced Brucella broth supplemented with yeast extract, l-cysteine, 5 μg/ml hemin, 1 μg/ml vitamin K1 and 5% (v/v) lacked sheep blood in triplicate. A bacterial suspension of approximately 10^8 cfu/mL from each strain was prepared and seeded into the 96-well plates. Plates were then incubated for 48 h at 37 °C under anaerobic conditions. MICs were determined as the lowest concentration of a given drug that suppressed the visual growth of bacteria. The MICs of VAN, MET and FDX as antibiotic controls were determined by agar dilution method according to CLSI criteria (document M100-S28) [44]. The clinical breakpoints for antimicrobial agents used in this study are those previously provided by Peng et al. [45]. A series of two-fold dilutions of each antibiotic with final concentrations ranging from 0.5 to 256 μg/ml for VAN and MET, and 0.5–16 μg/ml for FDX was made in pre-reduced supplemented Brucella broth. For inoculum preparation, test bacterial strains were cultured anaerobically on CCFA plates at 37 °C for 48 h. Then, pure bacterial cultures were suspended in pre-reduced 0.85% saline solution to yield McFarland 0.5 equivalent to a final concentration of approximately 1 × 10^8 CFU ml^{-1}. MICs were determined as the lowest concentration of a given drug at which no visual growth of bacteria was observed after incubation for 48 h at 37 °C in an anaerobic atmosphere. Growth controls were performed by addition of bacterial inoculum into the antibiotic-free medium.

**Cell culture and growth conditions**
The Vero (African green monkey kidney) and HT-29 (human colorectal adenocarcinoma) cell lines were obtained from Iranian Biological Resource Center (IBRC). The cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium (H-DMEM, Gibco, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 U/ml of penicillin, and 100 μg/ml of streptomycin in a 5% CO_2 humidified incubator at 37 °C. To prepare confluent monolayers (approximately 80%), Vero and HT-29 cells were dispensed into 96-well trays at 6 × 10^4 cells/well and 5 × 10^5 cells/well, respectively. The numbers of viable and dead cells in each treatment were assessed by trypan blue (Sigma, USA) exclusion assay. Briefly, the trypsinized cell suspension was diluted in 1:10 ratio using a 0.025% (w/v) trypan blue solution. Cell counting was performed using a Neubauer Improved Hemocytometer (PerciColor HBG, Germany).

**Cell cytotoxicity assay**
Cytopathic effect (CPE) of the toxins was determined by cell rounding assay using Vero cells as described previously with some modifications [46]. Two concentrations (100 and 500 μg/ml) of C. difficile culture-filtrate and Tox-S in H-DMEM were prepared with a total volume of 100 μl per well and were added to the Vero cell monolayers, and incubated them for 4 h at 37 °C in 5% CO_2. The CPE indicated by 90% cell rounding was then determined visually using an inverted microscope (Olympus Corporation, Tokyo, Japan) at × 400 magnification. The experiments were performed in triplicate.

Different concentrations of CAP (10, 20, 50 and 75 μM) and CCM (5, 10, 20 and 30) were freshly prepared in sterile distilled water and were added to the Vero cell monolayers, and incubated for 1, 4, 24 h at 37 °C in 5% CO_2. Different concentrations of CCM and CAP was not revealed the CPE on Vero cells after 24 h treatment. The experiments were performed in triplicate.

**Cell viability assay**
The cell viability of HT-29 cells exposed to different concentrations of natural products, C. difficile culture-filtrate, and Tox-S was measured using an MTT assay. Briefly, 5 × 10^5 cells/well were seeded in 96-well plates and allowed to adhere overnight. Cells were treated with different concentrations of CAP (10, 20, 50 and 75 μM) and CCM (5, 10, 20, 30 and 60 μM) for 24 h. Culture-filtrate and Tox-S (100 and 500 μg/ml) treated cells were incubated for 4 h as described previously [47]. Following incubation, 10 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was added to each well, and the cells were incubated for 4 h at 37 °C in 5% CO_2. The reaction was then stopped by lysing the cells with 200 μl of dimethyl sulfoxide (DMSO) for 15 min. Monolayers in the growth media were used as negative controls and wells without cells served as blanks. The plates were then incubated at 37 °C for 10 min and the optical density (OD) of each well was measured at
560 nm using a microplate reader (BioTek, USA). The cell viability was calculated using the equation Cell viability (%) = (X \times 100%)/Y, where “X” is the absorbance of treated cells and “Y” the absorbance of untreated cells.

**Treatment of HT-29 cells with culture-filtrate, Tox-S, CAP and CCM**

The highest concentrations of culture-filtrate (100 μg/ml) and Tox-S (100 μg/ml), and different concentrations of CAP (10, 20, 50 μM) and CCM (10, 20, 30 μM) with no visible effect on cell monolayers were used in this assay. Briefly, HT-29 cells were pre-treated with 100 μg/ml of *C. difficile* culture-filtrate and Tox-S, and incubated for 4 h at 37 °C in 5% CO2. After incubation, cells were treated with various over-mentioned concentrations of CAP and CCM for 24 h at 37 °C in 5% CO2 incubator. All treatments were run in triplicate. Untreated cells, culture-filtrate from non-toxigenic *C. difficile* ATCC 700057 and Tox-S from three other toxigenic strains without the addition of natural products were used as controls. After treatment, the cells were lysed for RNA extraction and gene expression analysis.

**RNA preparation and cDNA synthesis**

Total RNA from treated HT-29 cells was extracted using RNAasy Mini Kit (Qiagen, Germany) following the manufacturer’s protocol. RNA concentration and quality was assessed spectrophotometrically by using NanoDrop spectrophotometer (ND-1000, Thermo Scientific, USA). The RNA samples were frozen at −80 °C until used for cDNA synthesis. The RNA was reverse-transcribed to cDNA using the PrimeScript™ RT Reagent Kit (Takara, Japan) according to the manufacturer’s instructions. All cDNA preparations were frozen at −20 °C until further use.

**Quantitative real-time PCR (RT-qPCR)**

The RT-qPCR analysis was performed with the Rotor-Gene® Q (Qiagen, Germany) real-time PCR system using BioFACT™ 2X Real-Time PCR Master Mix (BIOFACT, South Korea). The oligonucleotide primers and amplification conditions used for gene expression analysis of BCL-2, SMAD3, TGF-β, TNF-α, and NF-κB are listed in Table 1. The β-actin housekeeping gene served as the reference gene. To confirm amplification specificity, a melting analysis and subsequent agarose gel electrophoresis were performed after each run. All reactions were run in triplicate. Relative gene expression was calculated by the $2^{-\Delta\Delta C_t}$ method, and the expression levels were given as the fold change relative to the control samples.

**Statistical analysis**

Statistical analysis was carried out with GraphPad Prism software version 5.04 (Inc., CA, USA). Unpaired student’s t test and one-way analysis of variance (ANOVA) were used to determine the statistical significance between groups. The data were presented as the averages of at least three independent experiments; error bars represent the standard deviations (SD). Differences were considered statistically significant when $P<0.05$; $^*P<0.05$, $^{**}P<0.01$, $^{***}P<0.001$ and $^{****}P<0.0001$.

**Results**

**Antimicrobial susceptibility testing**

The MIC of natural products and antibiotic controls examined against the four *C. difficile* strains were presented in Table 2. Both CAP and CCM showed an MIC of 256 μM for *C. difficile* RT 001 and RT 126, while a two-fold lower MIC (128 μM) was detected for *C. difficile* RT 084 and *C. difficile* strain ATCC 700057. In addition, all the four *C. difficile* strains were interpreted to be susceptible against antimicrobial controls tested in this work.

---

**Table 1 Oligonucleotide sequences used in this study**

| Target gene | Primer designation | Oligonucleotide sequence (5’-3’) | PCR conditions | Reference |
|-------------|-------------------|---------------------------------|----------------|-----------|
| BCL-2       | BCL-2             | F: GAGCTGGTGGTTGACTTTC           | 95 °C 10 min, 40 cycles (95 °C 10 s; 56 °C 35 s; 72 °C 20 s), 72 °C 5 min | [48]      |
|             |                   | R: TCCATCTCCGCTATCATCC          |                |           |
| TNF-α       | TNF-α             | F: AGCCCATATGTGAGCAACC          |                | [49]      |
|             |                   | R: TGGTACAGGCGCTCTTATG          |                |           |
| TGF-β       | TGF-β             | F: CAATCTCTGCGGATATCCAG         |                | [50]      |
|             |                   | R: GCAAATACTCCGCGATCATCAA       |                |           |
| NF-κB       | NF-κB             | F: CCAGACCAACAAACACCCT          |                | [51]      |
|             |                   | R: TACCTGCGGCATCTTGAGC          |                |           |
| SMAD3       | SMAD3             | F: GCCGTGGTGAGCAACCATCAT        |                | [52]      |
|             |                   | R: TGGCTCTCATGGTGTCCTT          |                |           |
| β-actin     | ACTBF             | F: ATGGAGCGGAGGACTTTRGATT       |                | [53]      |
|             |                   | R: AGTGGGGTGGTCATTAGGAT         |                |           |
Toxin-mediated cytotoxicity of *C. difficile* strains

To determine the CPE of the four *C. difficile* strains, two different concentrations of Tox-S (100 and 500 μg/ml) and culture-filtrate from non-toxigenic strain were used in cytotoxicity assay using Vero cells. The Tox-S of three toxigenic strains *C. difficile* RT 001, RT 126 and RT 084 caused loss of adhesion, and showed the highest CPE at concentration of 500 μg/ml to achieve 90% cell rounding as compared to culture-filtrate from non-toxigenic strain ATCC 700057 which had no visible effect on Vero cells. The microscopic cell morphology of Vero cells and induced CPE after treatment with Tox-S of the three toxigenic *C. difficile* strains in comparison with culture-filtrate from non-toxigenic strain are shown in Fig. 1.

### Table 2 Interpretative criteria and MIC values of CCM, CAP and antimicrobial agents tested against *C. difficile* strains

| Agents   | Interpretaion | MIC |
|----------|---------------|-----|
|          | S             | I   | R  |
| CCM (μM) |   –           | –   | –  |
| CAP (μM) |   –           | –   | –  |
| MET (μg/ml) | ≤ 8       | 16  | ≥ 32 |
| VAN (μg/ml) | ≤ 2       | NA  | ≥ 8  |
| FDX (μg/ml) | ≤ 1       | > 1 | NA  |

|          | RT 001 | RT 126 | RT 084 | 700057 |
| CCM (μM) |        |        |        |        |
| CAP (μM) |        |        |        |        |
| MET (μg/ml) |        |        |        |        |
| VAN (μg/ml) |        |        |        |        |

Breakpoints were defined as susceptible (S), intermediate resistant (I), or resistant (R) with reference to CLSI, EUCAST or published data. NA, not available

CCM curcumin, CAP capsaicin, MET metronidazole, VAN vancomycin, FDX fidaxomicin

Cytotoxicity of CAP and CCM

To determine the cytotoxic effects of CAP and CCM, Vero cells were incubated with different concentrations of CAP (10, 20, 50 and 75 μM) and CCM (5, 10, 20 and 30 μM) for 1, 4, 24 h. Stimulated Vero cells demonstrated that none of the natural products showed cytotoxic effects after 1 and 4 h. Of the indicated time points, both

---

**Fig. 1** Cytopathic effect (CPE) of two different concentrations (100 and 500 μg/ml) of Tox-S from *C. difficile* (RT 001, RT 126, RT 084) and culture-filtrate of *C. difficile* ATCC 700057 on Vero cells using microscopy. **A** Microscopic cell morphology of Vero cells after treatment with 100 μg/ml Tox-S and culture-filtrate for 4 h at 37 °C; **B** Microscopic cell morphology of Vero cells after treatment with 500 μg/ml Tox-S and culture-filtrate for 4 h at 37 °C; **C** Untreated Vero cell monolayer. **A, B** Light microscopy × 20, Scale bar = 50 μm, **C** Light microscopy × 40, Scale bar = 50
CAP and CCM showed moderate cytotoxic effects after 24 h of treatment as compared to untreated Vero cell monolayer (Figs. 2 and 3).

**Cell viability of HT-29 cells treated with C. difficile strains, CAP and CCM**

An MTT assay was performed to determine cell viability of HT-29 cells after exposure to different concentrations of Tox-S of the three toxigenic *C. difficile* strains and culture-filtrate from non-toxigenic strain compared to untreated control cells. As shown in Fig. 4A, only Tox-S of the three toxigenic strains at concentration of 500 µg/ml significantly (*P* < 0.05) reduced the cell viability of HT-29 cells in comparison with culture-filtrate from non-toxigenic strain and untreated control cells. In more details, the Tox-S of toxigenic *C. difficile* strains (RT 001, RT 126 and RT 084) at concentration of 100 µg/ml (80.7%, 84.4% and 73.8%, respectively) and 500 µg/ml (65.5%, 67.5% and 65.9%, respectively) decreased the cell viability of HT-29 cells after 4 h of treatment. The viability of cells after exposure to culture-filtrate from non-toxigenic strain was 91%. The effects of different concentrations of natural products on cell viability of HT-29 cells were also assessed by an MTT assay. The viability of cells after incubation with different concentrations of CAP (10, 20, 50 and 75 µM) and CCM (5, 10, 20 and 30 µM) was 94.1, 92, 88.5, 85.5 and 98.8, 98.5, 93.8, 92.4, respectively. HT-29 cells showed nearly 90% viability after the cells were treated with concentrations of 10, 20, 50 µM and 5, 10, 20, 30 µM for CAP and CCM, respectively (Fig. 4B). Totally, we did not observe any significant reduction in the viability of treated cells with different concentrations of CAP and CCM in comparison with untreated cells (*P* > 0.05).

![Fig. 2 Cytotoxic effect of capsaicin (CAP) on Vero cells.](image)

A Microscopic cell morphology of Vero cells after treatment with the indicated concentrations of CAP for 1 h at 37 °C; B Microscopic cell morphology of Vero cells after treatment with the indicated concentrations of CAP for 4 h at 37 °C; C Microscopic cell morphology of Vero cells after treatment with the indicated concentrations of CAP for 24 h at 37 °C; D Untreated Vero cell monolayer. Light microscopy × 20, Scale bar = 50 µm
**C. difficile** downregulates the gene expression level of BCL-2 and upregulates the expression of SMAD3 and inflammation-related genes in treated HT-29 cells

As shown in Fig. 5, treatment of HT-29 cells with Tox-S (100 µg/ml) of *C. difficile* (RT 001, RT 126, RT 084) and culture-filtrate (100 µg/ml) of *C. difficile* ATCC 700057 significantly (*P < 0.001; *P < 0.001; *P < 0.001, *P < 0.01) reduced the expression level of BCL-2 after 4 h. Although not statistically significant (*P > 0.05), Tox-S (100 µg/ml) of *C. difficile* (RT 001, RT 126, RT 084) and culture-filtrate (100 µg/ml) of *C. difficile* ATCC 700,057 upregulated the gene expression level of SMAD3. Tox-S (100 µg/ml) of *C. difficile* RT 001, RT 084 significantly upregulated the gene expression level of TGF-β (*P < 0.05). Only Tox-S of *C. difficile* RT 084 significantly upregulated the gene expression level of NF-κB (*P < 0.05; *P < 0.05; *P < 0.01). The gene expression level of TNF-α was significantly increased by Tox-S of *C. difficile* (RT 001, RT 126, RT 084) after 4 h of treatment (*P < 0.05; *P < 0.05; *P < 0.05).

**CAP significantly decreased the gene expression level of BCL-2 and SMAD3 in Tox-S treated HT-29 cells**

The gene expression level of BCL-2 and SMAD3 in HT-29 cells were examined upon treatment with Tox-S (100 µg/ml) from *C. difficile* (RT 001, RT 126, RT 084), culture-filtrate (100 µg/ml) of *C. difficile* ATCC 700057, and different concentrations of CAP (10, 20, 50 µM). As shown in Fig. 6A, almost all concentrations of CAP decreased the gene expression level of BCL-2 in *C. difficile* stimulated HT-29 cells. In more details, the high concentration of CAP (50 µM) significantly downregulated BCL-2 expression level in HT-29 cells treated with Tox-S of *C. difficile*.
RT 001 ($P < 0.05$), RT 084 ($P < 0.05$) and culture-filtrate of strain ATCC 700054 ($P < 0.05$). Also, the high concentrations of CAP (20 and 50 µM) significantly reduced the gene expression of SMAD3 in HT-29 cells treated with Tox-S of C. difficile RT 001 ($P < 0.01; P < 0.0001$), RT 126 ($P < 0.001; P < 0.0001$) and culture-filtrate of strain ATCC 700054 ($P < 0.0001; P < 0.0001$) as shown in Fig. 6B.

**Effects of CAP on gene expression level of inflammation-related genes in Tox-S stimulated HT-29 cells**

To evaluate the effects of CAP on gene expression level of NF-κB, TGF-β and TNF-α, different concentrations of CAP (10, 20, 50 µM) were added to Tox-S stimulated HT-29 cells. As shown in Fig. 6C, CAP used in all different concentrations (10, 20, 50 µM) significantly ($P < 0.01; P < 0.001$) reduced the NF-κB gene expression in stimulated HT-29 cells with Tox-S of C. difficile RT 126. Also, the highest concentration of CAP (50 µM) was able to significantly ($P < 0.0001$) downregulate the NF-κB gene expression only in stimulated HT-29 cells with culture-filtrate of strain ATCC 700054. As shown in Fig. 6D, almost all different concentrations of CAP (10, 20, 50 µM) slightly decreased the TGF-β gene expression in Tox-S stimulated HT-29 cells, although the differences did not reach statistical significance ($P > 0.05$). Also, all different concentrations of CAP (10, 20, 50 µM) caused statistically significant reductions in TNF-α gene expression of stimulated HT-29 cells with Tox-S of C. difficile RT 001 ($P < 0.001; P < 0.001$) and culture-filtrate of strain ATCC 700057 ($P < 0.05; P < 0.05; P < 0.05$) compared with HT-29 cells treated with Tox-S of C. difficile RT 084 and RT 126 (Fig. 6E). Moreover, it could be suggested that reduction in TNF-α gene expression is independent of the concentrations of CAP used in this work.

**CCM decreased the gene expression level of BCL-2 and SMAD3 in Tox-S treated HT-29 cells**

To examine the effects of CCM on gene expression level of BCL-2 and SMAD3, different concentrations of CCM (10, 20, 30 µM) were added to Tox-S stimulated HT-29 cells. As shown in Fig. 7A, different concentrations of CCM decreased the gene expression of BCL-2 in Tox-S stimulated HT-29 cells. As shown in Fig. 7A, different concentrations of CCM decreased the gene expression of BCL-2 in Tox-S stimulated HT-29 cells. In more details, all concentrations of CCM significantly downregulated the gene expression of BCL-2 in stimulated HT-29 cells with culture-filtrate of strain ATCC 700054 ($P < 0.05; P < 0.01; P < 0.001$). Also, all concentrations of CCM reduced the gene expression of SMAD3 in HT-29 cells treated with Tox-S of C. difficile (RT 001, RT 126, RT 084), and culture-filtrate of strain ATCC 700054 as shown in Fig. 7B. However, these reductions were not statistically significant ($P > 0.05$).
Effects of CCM on expression level of inflammation-related genes in Tox-S treated HT-29 cells

The effects of different concentrations (10, 20, 30 µM) of CCM on gene expression of TNF-α, NF-κB, and TGF-β were also investigated in HT-29 cells treated with Tox-S of toxigenic strains and culture-filtrate of the non-toxigenic strain. As shown in Fig. 7C, almost all different concentrations of CCM decreased the NF-κB gene expression in Tox-S stimulated HT-29 cells. Of note, lower concentrations of CCM (10 and 20 µM) significantly downregulated the gene expression NF-κB in HT-29 cells stimulated with Tox-S of *C. difficile* RT 084 (*P* < 0.001; *P* < 0.01) and RT 126 (*P* < 0.001; *P* < 0.01). Similarly, CCM decreased the gene expression of TGF-β in Tox-S stimulated HT-29 cells (Fig. 7D). However, these reductions were not significantly different (*P* > 0.05), except for HT-29 cells treated with culture-filtrate of strain ATCC 700054 (*P* < 0.001; *P* < 0.001; *P* < 0.001).

Also, all different concentrations of CCM decreased the TNF-α gene expression in Tox-S and culture-filtrate of strain ATCC 700054 stimulated HT-29 cells. As shown in Fig. 7E, the higher concentrations of CCM (20 and 30 µM) significantly decreased the TNF-α gene expression in HT-29 cells stimulated with Tox-S of *C. difficile* RT 001 (*P* < 0.0001; *P* < 0.0001), RT 084 (*P* < 0.0001; *P* < 0.0001) and RT 126 (*P* < 0.0001; *P* < 0.0001).

Discussion

The two major toxins, TcdA and TcdB, have long been identified as the primary virulence factors of *C. difficile*, which are also associated with the inflammatory response induced during CDI [7]. These exotoxins disrupt host cell function and induce mucosal inflammation through inactivation of small GTP-binding proteins including Rho, Rac, and Cdc42 [54] (Fig. 8). Because of the scarcity of anti-clostridial options and
rapid rise in emerging hypervirulent \textit{C. difficile} isolates, the management of CDI has become a global healthcare challenge. Accordingly, exploring novel complementary and alternative therapeutic agents is of great interest in either treating or preventing of CDI \cite{54–56}. So far, a few studies have been carried out to examine the effects of inhibitory properties of CCM and CAP on \textit{C. difficile} toxin activity \cite{41, 42, 57}. Hence, the present study addressed the effect of natural products, CCM and CAP, on \textit{C. difficile} using HT-29 cells treated with Tox-S (100 μg/ml) from \textit{C. difficile} (RT 001, RT 126, RT 084), culture-filtrate (100 μg/ml) of \textit{C. difficile} ATCC 700057, and different concentrations (10, 20, 50 μM) of capsaicin (CAP) measured by using quantitative real-time PCR assay. Gene expression data were normalized to β-actin as the reference gene. Data were presented as mean±SD from three independent experiments. A \textit{P} value of <0.05 was considered as significant (*\textit{P}<0.05; **\textit{P}<0.01) by unpaired student’s \textit{t} test and one-way ANOVA statistical analysis.

Fig. 6 Relative expression of BCL-2 \textbf{A}, SMAD3 \textbf{B}, NF-kB \textbf{C}, TGF-β \textbf{D} and TNF-α \textbf{E} genes in HT-29 cells upon treatment with Tox-S (100 μg/ml) from \textit{C. difficile} (RT 001, RT 126, RT 084), culture-filtrate (100 μg/ml) of \textit{C. difficile} ATCC 700057, and different concentrations (10, 20, 50 μM) of capsaicin (CAP) measured by using quantitative real-time PCR assay. Gene expression data were normalized to β-actin as the reference gene. Data were presented as mean±SD from three independent experiments. A \textit{P} value of <0.05 was considered as significant (*\textit{P}<0.05; **\textit{P}<0.01) by unpaired student’s \textit{t} test and one-way ANOVA statistical analysis.
Mody et al. different bioactive components of CCM were more effective than FDX in growth inhibition of *C. difficile* strains at concentrations ranging from 4 to 32 µg/ml [57]. These controversial results can be due to different strains of *C. difficile* examined with varied resistance potency in each study. Moreover, this inconsistency may arise from the difference in the nature of phytoconstituents tested, as the activity of each component was varied in the later study. In addition, and to the best of our knowledge, no published studies have previously shown the inhibitory growth effect of CAP on *C. difficile*. Based on our results, CAP can inhibit the growth of different *C. difficile* clinical strains at concentrations ranging from 128 to 256 µM. However, further research using a larger cohort of clinical strains is required to decipher the growth inhibitory action of CAP on *C. difficile* bacteria.

Apoptosis, also known as programmed cell death, is an essential cell process which controls various cellular activities such as the cell turnover and immune response function [58]. A number of proteins, in particular anti-apoptotic B-cell lymphoma 2 (BCL-2) family members, have long been known as an apoptosis suppressor [59]. It has been well established that both TcdA and TcdB from
C. difficile strains are able to induce cell apoptosis in vitro and in vivo.[11]. In addition, and in consistent with the current concept that toxin induces apoptosis in epithelial cells [60, 61], our treatment experiments indicated that mRNA expression level of BCL-2 was notably decreased upon treatment of HT-29 cells with Tox-S of toxigenic strains and culture-filtrate of C. difficile ATCC 700057. However, Tox-S from toxigenic strains could more strongly decrease the gene expression level of BCL-2 in HT-29 cells when compared to untreated control. It is
now established that both toxins A and B provoke a complex cascade of host cellular responses and are ultimately responsible for clinical symptoms, inflammation and tissue necrosis [62]. However, it is increasingly appreciated that non-toxin virulence factors likely play essential roles in C. difficile colonization, maintenance in the intestinal tract and promotion of potent pro-inflammatory activities [63]. This apoptotic effect can be recognized by cell rounding phenotype in cultured cell lines as observed in our study. CCM is a well-known anti-proliferative component [28] that exhibits an apoptotic effect similar to the toxin A and B of C. difficile [7, 10]. It has been reported that CCM can promote the apoptosis cascade particularly through the downregulation of BCL-2 in different cancer cell types [64, 65]. CAP, with a structure similar to that of CCM [66], has several physiological and pharmacological effects with different mechanisms of action [30]. Accumulated studies have shown that CAP can trigger apoptosis in a numerous cancer cell type, however its precise molecular mechanism remains to be elucidated [39, 67, 68]. To date, different studies have investigated the role of CCM and CAP in modulating mRNA expression of BCL-2 [65, 69, 70]. Jung et al. showed that CAP reduced the BCL-2 expression and consequently induced apoptosis in SK-Hep-1 cells [23]. Yang et al. also demonstrated that CCM could induce cell apoptosis via decreasing the ratio of anti-apoptotic BCL-2 in varying concentrations of CCM (100 mg/kg, 50 mg/kg, and 25 mg/kg) [65]. However, further in vitro and in vivo investigations are required to precisely understand the relevant mechanisms and signaling pathways by which CCM or CAP promote apoptosis in CDI.

TGF-β is a pleiotropic cytokine that modulates various cellular processes like cell differentiation, apoptosis and immunosuppression [71, 72]. There is clear evidence that C. difficile toxin A induces TGF-β1 mRNA expression level in ileal-loop tissues of mice and rat small intestinal epithelial cell lines [71]. Furthermore, it has been reported that treatment of T84 human colon adenocarcinoma cell line with low concentration of TcdA (< 10 ng/ml) enhanced the mRNA expression of TGF-β1. This effect was associated with induction of TGF-β1 and its receptor, TβRII, phosphorylation and nuclear translocation of SMAD2/3 in both in vitro and in vivo experiments [72]. These findings strongly suggest that TcdA induces activation of the TGF-β1 pathway through canonical SMAD signaling [71]. The current study showed that strains RT 084 (TcdA“B”+) induced the highest expression level of TGF-β1 and SMAD3 in comparison with the other strains. The higher expression level of TGF-β1 and SMAD3 by RT 084 could be owing to overproduction of TcdA in this strain or may be due to the existence of other virulence metabolites in its extracted Tox-S. In addition, RT 084 strains were reported to be more prevalent amongst patients with antibiotic-associated diarrhea and CDI in Algeria, Ghana and Iran [73–75]. This finding highlights the significance of other putative virulence factors in the pathogenesis of various C. difficile strains that remains to be elucidated. Results from this study as well as previous studies [71] suggested that this signaling pathway might play a protective role against the effect of toxin-mediated cytotoxicity of C. difficile (Fig. 8). NF-κB is one of the well-known regulatory factors that controls transcription of various pro-inflammatory cytokines and chemokines involved in intestinal immune system [76]. Several studies demonstrated that TcdA and TcdB induce remarkable immune response and stimulate the release of inflammatory cytokines in the gut [77, 78]. Li et al. showed that TcdB significantly activates MAPKs, NF-κB and subsequently induces production of IL-1β and TNF-α [79]. Our data showed that all different C. difficile RTs induced the gene expression of NF-κB and TNF-α in treated intestinal HT-29 cells as compared to non-infected control cells. Interestingly, culture-filtrate of non-toxigenic C. difficile ATCC 700057 significantly induced the expression level of NF-κB similar to toxigenic strains used in this work. According to a previous study, proteomic analysis of C. difficile revealed that several other virulence factors such as extracellular proteases, surface layer proteins (SLP) A, cell wall-binding protein (CWP), collagen-binding protein (CbpA), fibronectin-binding protein (FBP) type IV pili and flagella can also contribute to disease severity and host colonization [80–83]. These bacterial factors possess potent pro-inflammatory activities, and are capable of causing intestinal mucosal injury by promoting inflammatory responses [80, 84–86]. For instance, recognition of C. difficile flagellin by toll-like receptor 5 (TLR-5) results in activation of NF-κB and MAPKs pathways, which in turn can induce the production of additional growth factors and cytokines [87]. Therefore, this finding once again highlights the clinical significance of non-toxigenic strains and could shed light on the role of non-toxin virulence factors in the pathogenesis of C. difficile. According to several previous studies, CCM has anti-inflammatory and also anti-fibrosis effects by suppressing the NF-κB and TGF-β1/SMAD-3 signaling pathways, respectively (Fig. 8) [88–90]. Vasanthkumar et al. demonstrated that CCM and CAP alone or in combination cause considerable reduction in LPS-induced overexpression of COX-2, IL-6 and TGF-β [91]. Consistent with previous studies [92, 93], findings of the present work revealed that CCM could decrease the C. difficile-induced gene expression level of NF-κB,
Abbreviations
ANOVA: One-way analysis of variance; BCL-2: B-cell lymphoma 2 family members; BHI: Brain heart infusion broth; CAP: Capsaicin; CCM: curcumin; CCFA: Cycloserine-cefoxitin-fructose agar; CDI: Clostridioides difficile infection; CPE: Cytopathic effect; DMSO: Dimethyl sulfoxide; ELISA: Enzyme-linked immunosorbent assay; FDX: Fidaxomicin; IBC: Iranian Biological Resource Center; IECs: Intestinal epithelial cells; LCGT: Large clostridial glycosylating toxin; MDR: Multidrug resistant; MET: Metronidazole; MIC: Minimum inhibitory concentration; MTT: 3-(4,5 Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; OD: Optical density; RT-qPCR: Quantitative real-time PCR; rCDI: Recurrence rate; rpm: revolutions per minute; SD: Standard deviations; SDW: Sterile distilled water; TGF-β1/SMAD-3 and TNF-α in HT-29 cells stimulated by C. difficile strains. Moreover, Jingshuang et al. demonstrated that capsaicin reduced the secretion of inflammatory cytokines and TNF-α by inhibiting the NF-κB, and thereby reduced LPS-induced inflammatory response in macrophages [94]. Sugiyama et al. also showed that CAP attenuates TGFβ2-induced epithelial-mesenchymal-transition and reduced TGFβ2-induced p-Smad2/3 in lens epithelial cells in vivo and in vitro [95]. In the same manner, CAP was able to reduce the gene expression level of NF-κB and TGF-β1/SMAD-3 in the present study, however further study is needed to investigate its potential anti-inflammatory effect.

Conclusion
In conclusion, the results of the present study indicated that both CCM and CAP can modulate the mRNA expression of BCL-2, TGF-β, SMAD3, NF-κB, and TNF-α in HT-29 cells stimulated by different clinical C. difficile strains in vitro. Also, we demonstrated the growth inhibitory potential of these two natural products, and which can be utilized as anti-clostridial agents to ameliorate C. difficile toxin-induced inflammation. The analysis of biological pathways and networks associated to herbal medicines is complicated due to complexity of their derivatives and targets. Further research exploring the inhibitory effect of CCM and CAP and their related components on other key virulence attributes expressed by various C. difficile isolates, on C. difficile endospore production, germination and outgrowth, and their activity in vivo are worth to be performed. Taken together, ease of availability and affordability of CCM and CAP can introduce them as potential supplements to current treatments used for refractory C. difficile infections. However, further studies are needed to accurately explore the mechanistic basis for the anti-toxin activity of such natural components, their beneficial effects, safety and also possible adverse risks in clinical practice through pre-clinical and/or clinical studies.

References
1. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–16.
2. Freeman J, et al. The changing epidemiology of Clostridium difficile infection in a model of Pseudomembranous colitis. Nat Commun. 2018;9(1):1–10.
3. Dingle KE, et al. Clostridium difficile: clonality and pathogenicity locus diversity. PloS ONE. 2011;6(5):e19993.
4. Rupnik M, Wilcox MH, Gerdin DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7(7):526–36.
5. Crobath MJ, et al. Understanding Clostridium difficile colonization. Clin Microbiol Rev. 2018;31(2):e00021-e117.
6. Jank T, Belyi Y, Aktores K. Bacterial glycosyltransferase toxins. Cell Microbiol. 2015;17(12):1752–65.
7. Di Bella S, et al. Clostridium difficile toxins A and B: insights into pathogenic properties and extraintestinal effects. Toxins. 2016;8(5):134.
8. Saavedra PH, et al. Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of Pseudomembranous colitis. Nat Commun. 2018;9(1):1–10.
9. Gerhard R, et al. Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J Med Microbiol. 2008;57(6):765–70.

10. Chandrasekar R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723–50.

11. Matte I, et al. Antiprotective properties of Bcl-2 and Bcl-XL inhibit Clostridium difficile toxin A-induced cell death in human epithelial cells. Infect Immun. 2009;77(12):5400–10.

12. Nottrott S, et al. Clostridium difficile toxin A-mediated apoptosis is p53-independent but depends on glucosylation of Rho GTPases. Apoptosis. 2007;12(8):1443–53.

13. Matarrese P, et al. Clostridium difficile toxin B causes apoptosis in epithelial cells by thrilling mitochondria: involvement of ATP-sensitive mitochondrial potassium channels. J Biol Chem. 2007;282(12):9299–41.

14. Miller BA, et al. Comparison of the burdens of hospital-onset, health-care facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32(4):387–90.

15. Oosterveer RE, et al. Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect. 2018;24(5):452–62.

16. Østensen M. The use of biologics in pregnant patients with rheumatic disease. Expert Rev Clin Pharmacol. 2017;10(6):661–9.

17. Martin J, Wilcox M. New and emerging therapies for Clostridium difficile infection. Curr Anti Infect Dis. 2016;2(6):546–54.

18. Wilcox MH, et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. J Antimicrob Chemother. 2017;72(9):2647–56.

19. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile associated diarrhoea in adults. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD004610.pub5.

20. Burton HE, Mitchell SA, Watt M. A systematic literature review of economic evaluations of antibiotic treatments for Clostridium difficile infection. Pharmacoeconomics. 2017;35(11):1123–40.

21. Spigaglia P. Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection. Ther Adv Infect Dis. 2016;3(1):23–42.

22. O'Neill J, et al. Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev. 2008;75(4):139–71.

23. Jung MY, Kang HJ, Moon A. Capsaicin-induced apoptosis in SK-Hep-1 hepatocarcinoma cells involves Bcl-2 downregulation and caspase-3 activation. Cancer Lett. 2001;165(2):139–45.

24. Funir R, Zündorf I. Plant-derived anti-inflammatory compounds: hopes and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediators Inflamm. 2014;2014:146832.

25. Forni C, et al. Beneficial role of phytochemicals on oxidative stress and age-related diseases. Biomed Res Int. 2019;2019:874253.

26. Abdul Manas AS, et al. Synergistic effects of curcumin and piperine as potent acetylcholine and amyloidogenic inhibitors with significant neuroprotective activity in sh-sysy cells via computational molecular modeling and in vitro assay. Front Aging Neurosci. 2019;11:206.

27. Upadhayay A, et al. Inhibiting microbial toxins using plant-derived compounds and plant extracts. Medicines (Basel). 2015;2(3):186–211.

28. Friedman M, Rasooly R. Review of the inhibition of biological activities and disappointments regarding the translation of preclinical knowledge into clinical progress. Mediators Inflamm. 2014;2014:146832.

29. Goel A, Kummaruktakar AB, Aggarwal BB. Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787–809.

30. Sharma SK, Vij AS, Sharma M. Mechanisms and clinical uses of capsaicin. Protein Cell. 2017(8):169–77.

31. Hayman M, Kam PC. Capsaicin: a review of its pharmacology and clinical applications. Curr Anaesth Crit Care. 2008;19(5–6):338–43.

32. Nascimento PL, et al. Quantification, antioxidant and antimicrobial activity of phenolics isolated from different extracts of Capsicum frutescens (Pimenta Malaguatea). Molecules. 2014;19(4):5434–47.

33. Azimirad M, et al. Coexistence of Clostridiods difficile and Staphylococcus aureus in gut of Iranian outpatients with underlying inflammatory bowel disease. Anaerobe. 2020;61:102111.

34. Roshan N, Riley TV, Hammer KA. Antimicrobial activity of natural products against Clostridium difficile in vitro. J Appl Microbiol. 2017;123(1):92–103.

35. Roshan N, et al. Effect of natural products on the production and activity of Clostridium difficile toxins in vitro. Sci Rep. 2018;8(1):15735.

36. Betts JW, et al. In vitro antibacterial activity of curcumin-polymin b combinations against multidrug-resistant bacteria associated with traumatic wound infections. J Nat Prod. 2016;79(6):1702–6.

37. Yang F, Zheng J. Understand spiciness: mechanism of TRPV1 channel activation by capsaicin. Protein Cell. 2017(8):169–77.

38. Hayman M, Kam PC. Capsaicin: a review of its pharmacology and clinical applications. Curr Anaesth Crit Care. 2008;19(5–6):338–43.

39. Wayne PA (2018) Clinical and Laboratory Standards Institute (CLSI) performance standards for antimicrobial susceptibility testing, 28th edn. Approved standard, CLSI document M100-S28.

40. Peng J, et al. Antibiotic resistance and toxin production of Clostridium difficile isolates from the hospitalized patients in a large hospital in Florida. Front Microbiol. 2017;8:2584.

41. Li S, et al. Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autolocleavage and release of the glycosyltransferase domain into the host cell cytosol. Pathog Dis. 2013;69(1):11–8.

42. Guo S, et al. Two lactobacillus species inhibit the growth and α-toxin production of Clostridium perfringens and induced proinflammatory factors in chicken intestinal epithelial cells in vitro. Front Microbiol. 2017;8:2081.

43. Zhao S, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits the viability of MDS and AML cells by suppressing JAK2/STAT3 signaling. Am J Transl Res. 2016;8(7):3169–78.

44. Jin Y, et al. X-linked inhibitor of apoptosis protein accelerates migration by inducing epithelial-mesenchymal transition through TGF-β signaling pathway in esophageal cancer cells. Cell Biosci. 2019;7:6.

45. Kouser L, et al. Human properdin opsonizes nanoparticles and triggers a potent pro-inflammatory response by macrophages without involving complement activation. Front Immunol. 2018;9:131.

46. Bhat SM, et al. Ethyl pyruvate reduces organic dust-induced airway inflammation by targeting HMGB1-RAGE signaling. Respir Res. 2019;20(1):1–9.

47. Peng J, et al. Hypoxia-inducible factor 1α regulates the transforming growth factor β1/SMAD family member 3 pathway to promote breast cancer progression. J Breast Cancer. 2018;21(3):259–66.

48. Ofinran O, et al. Selection of suitable reference genes for gene expression studies in normal human ovarian tissues, borderline-ovarian tumours and ovarian cancer. Mol Med Rep. 2016;14(6):5725–31.

49. Pruit RN, Lacy DB. Toward a structural understanding of Clostridium difficile toxins A and B. Front Cell Infect Microbiol. 2012;2:228.

50. Wehrhahn MC, et al. A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain. Anaerobe. 2019;55:117–24.

51. Hinksin PL, et al. Tolevamer, an anionic polymer, neutralizes toxins produced by the B/027 strains of Clostridium difficile. Antimicrob Agents Chemother. 2008;52(6):2190–5.

52. Mody D, Athamneh AIM, Seleem MN. Curcumin: a natural derivative with antibacterial activity against Clostridium difficile. J Glob Antimicrob Resist. 2020;21:154–61.

53. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495–516.

54. Cazabot PE, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49–63.

55. Chen S, et al. Salubrinal protects against Clostridium difficile toxin B-induced CT26 cell death. Acta Biochim Biophys Sin (Shanghai). 2017;49(3):228–37.

56. Zhang Y, et al. Clostridium difficile toxin B recombinant protein inhibits tumor growth and induces apoptosis through inhibiting Bcl-2 expression,
triggering inflammatory responses and activating C-erbB-2 and Cox-2 expression in breast cancer mouse model. Biomed Pharmacother. 2018;101:391–8.

62. Viswanathan V, Mallozzi M, Vedantam G. Clostridium difficile infection: An overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes. 2010;1(4):234–42.

63. Vedantam G, et al. Clostridium difficile infection: toxins and non-toxin virulence factors, and their contributions to disease establishment and host response. Gut micro. 2012;3(2):121–34.

64. Rao J, et al. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-sensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells. J Transl Med. 2011;9:71.

65. Yang J, et al. Effect of curcumin on Bcl-2 and Bax expression in nude mice prostate cancer. Int J Clin Exp Pathol. 2015;8(8):9272–8.

66. Suresh D, Srinivasan K. Tissue distribution & elimination of capsacin, piperine & curcumin following oral intake in rats. Indian J Med Res. 2010;131:682–91.

67. Clark R, Lee SH. Anticancer properties of capsacin against human cancer. Anticancer Res. 2016;36(3):837–43.

68. Zimmer AR, et al. Antioxidant and anti-inflammatory properties of Capsicum baccatum: from traditional use to scientific approach. J Ethnopharmacol. 2012;139(1):228–33.

69. Yu J, et al. Curcumin induces apoptosis involving bax/bcl-2 in human hepatoma SMMC-7721 cells. Asian Pac J Cancer Prev. 2011;12(8):1925–9.

70. Lin C-H, et al. Capsaicin causes cell cycle arrest and apoptosis in human KB cancer cells. BMC Complement Altern Med. 2013;13(1):1–9.

71. Tinoco-Veras CM, et al. Transforming growth factor β1/SMAD signaling pathway activation protects the intestinal epithelium from Clostridium difficile toxin A-induced damage. Infect Immun. 2017;85:10. https://doi.org/10.1128/IAI.00430-17.

72. Johal SS, et al. Differential effects of varying concentrations of clostridium difficile toxin A on epithelial barrier function and expression of cytokines. J Infect Dis. 2004;189(11):2110–9.

73. Abda D, et al. First molecular characterisation and PCR ribotyping of Clostridium difficile strains isolated in two Algerian Hospitals. J Infect Dev Ctries. 2018;12:01.

74. Janssen I, et al. High prevalence of nontoxicogenic Clostridium difficile isolated from hospitalized and non-hospitalized individuals in rural Ghana. Int J Med Microbiol. 2016;306(8):652–6.

75. Azimirad M, et al. Clostridiodides difficile nontoxigenic strains isolated in two together hospitals. J Med Microbiol. 2016;306(8):652–6.

76. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun. 2012;4(2):149–58.

77. Foschetti DA, et al. Clostridium difficile toxins or infection induce up-regulation of adenosine receptors and IL-6 with early pro-inflammatory and late anti-inflammatory pattern. Braz J Med Biol Res. 2020;53(9):e9877.

78. Li Y, et al. Clostridium difficile toxic B induces colonic inflammation through the TRIM46/DUSP1/MAPKs and NF-κB signaling pathway. Cell Res. 2017;27:17023.

79. Chen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun. 2012;4(2):149–58.

80. Pechiné S, et al. Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol. 2005;54(2):193–6.

81. Wright A, et al. Immunoreactive cell wall proteins of Clostridium difficile identified by human sera. J Med Microbiol. 2008;57(6):750–5.

82. Janier C. Virulence factors of Clostridium difficile and their role during infection. Anaerobe. 2016;37:13–24.

83. Pechiné S, et al. Targeting Clostridium difficile surface components to develop immunotherapeutic strategies against clostridium difficile infection. Front Microbiol. 2018;9:1000.

84. Batah J, et al. Clostridium difficile flagella induce a pro-inflammatory response in intestinal epithelium of mice in cooperation with toxins. Sci Rep. 2017;7(1):3256–3256.

85. Nibbering B, et al. Host immune responses to clostridiodides difficile toxins and beyond. Front Microbiol. 2021. https://doi.org/10.3389/fmicb.2021.804949.

86. Hajam IA, et al. Bacterial flagellin—a potent immunomodulatory agent. Exp Mol Med. 2017;49(9):e373–e373.

87. Batah J, Kansau I. Intestinal epithelial cell response to Clostridium difficile flagella, in Clostridium difficile. New York: Springer; 2016. p. 103–16.

88. Olivera A, et al. Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol. 2012;12(2):368–77.

89. Liu D, et al. Curcumin inhibits transforming growth factor β induced differentiation of mouse lung fibroblasts to myofibroblasts. Front Pharmacol. 2016;7:419.

90. Marquardt JI, et al. Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer. J Hepatol. 2015;63(3):661–9.

91. Vasanthkumar T, Hanumanthappa M, Lakshminarayana R. Curcumin and capsaiacin modulates LPS induced expression of COX-2, IL-6 and TGF-β in human peripheral blood mononuclear cells. Cytotechnology. 2019;71(5):963–76.

92. Yu R, et al. Modulation of select immune responses by dietary capsaiacin. Int J Vitam Nutr Res. 1998;68(2):114–9.

93. Park JY, et al. Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages RAW 264.7: a PPARgamma ligand-like action as a novel mechanism. FEBS Lett. 2004;572(1–3):266–70. https://doi.org/10.1016/j.febslet.2004.06.084.

94. Li J, et al. Capsaicin affects macrophage anti-inflammatory activity via the MAPK and NF-κB signaling pathways. Int J Vitam Nutr Res. 2021. https://doi.org/10.1055/a-0007-21.

95. Sugiyama Y, et al. Capsaiacin attenuates TGFβ2-induced epithelial-mesenchymal-transition in lens epithelial cells in vivo and in vitro. Exp Eye Res. 2021;213:108840.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.